Leerink Partners Cautious on Moderna (MRNA): 'Tick Tick Tick – Getting More Cautious on CMV as Timelines Drag on'
Tweet Send to a Friend
Leerink Partners analyst Mani Foroohar reiterated an Underperform rating and $31.00 price target on Moderna (NASDAQ: MRNA).The analyst comments "Bottom ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
